In conclusion, our findings suggest that brain tau pathology appears to be reduced with increased BG‐EPVS, especially in individuals with cognitive impairment, pathological amyloid burden, or genetic Alzheimer's disease risk. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.